The genetics of familial combined hyperlipidaemia

Nature Reviews Endocrinology

Volumn 8, Issue 6, 2012, Pages 352-362

  Brouwers, Martijn C G J ^a   Van Greevenbroek, Marleen M J ^a   Stehouwer, Coen D A ^a   De Graaf, Jacqueline ^b   Stalenhoef, Anton F H ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; APOLIPOPROTEIN B; GLUCOKINASE; LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; FAMILIAL HYPERLIPEMIA; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC LINKAGE; GENETIC TRAIT; GENETIC VARIABILITY; GENETICS; HUMAN; LIPID STORAGE; LIPIDOMICS; LIPOPROTEIN BLOOD LEVEL; LIVER FATTY DEGENERATION; METABOLISM; METABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ADIPOSE TISSUE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPID METABOLISM; POLYMORPHISM, GENETIC; PREVALENCE;

EID: 84861329705     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.15     Document Type: Review

References (150)

1. Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L. & Motulsky, A. G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52, 1544-1568 (1973).
2. Sniderman, A. D., Ribalta, J. & Castro Cabezas, M. How should FCHL be defined and how should we think about its metabolic bases? Nutr. Metab. Cardiovasc. Dis. 11, 259-273 (2001). (Pubitemid 33686216)
3. Ayyobi, A. F. et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 23, 1289-1294 (2003). (Pubitemid 36871286)
4. Veerkamp, M. J. et al. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 22, 274-282 (2002). (Pubitemid 34127039)
5. Jarvik, G. P. et al. Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler. Thromb. Vasc. Biol. 14, 1687-1694 (1994).
6. Brouwers, M. C. et al. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus. Curr. Opin. Lipidol. 21, 530-538 (2010).
7. Pollex, R. L. & Hegele, R. A. Complex trait locus linkage mapping in atherosclerosis: time to take a step back before moving forward? Arterioscler Thromb. Vasc Biol. 25, 1541-1544 (2005). (Pubitemid 41098919)
8. Bodnar, J. S. et al. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat. Genet. 30, 110-116 (2002).
9. Nohara, A. et al. High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 27, 923-928 (2007). (Pubitemid 46606726)
10. Salazar, J. et al. Two novel single nucleotide polymorphisms in the promoter of the cellular retinoic acid binding protein II gene (CRABP-II). Mol. Cell Probes. 17, 21-23 (2003). (Pubitemid 36287306)
11. Meex, S. J. et al. The ATF6-Met[67]Val substitution is associated with increased plasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 29, 1322-1327 (2009).
12. Pajukanta, P. et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat. Genet. 36, 371-376 (2004). (Pubitemid 38437259)
13. Coon, H. et al. Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides. Hum. Genet. 117, 444-451 (2005). (Pubitemid 41236365)
14. Huertas-Vazquez, A. et al. Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler. Thromb. Vasc. Biol. 25, 1985-1991 (2005). (Pubitemid 41243473)
15. Coon, H. et al. TXNIP gene not associated with familial combined hyperlipidemia in the NHLBI Family Heart Study. Atherosclerosis 174, 357-362 (2004). (Pubitemid 38597094)
16. van der Vleuten, G. M. et al. Can we exclude the TXNIP gene as a candidate gene for familial combined hyperlipidemia? Am. J. Med. Genet. A 140, 1010-1012 (2006).
17. van der Vleuten, G. M. et al. Thioredoxin interacting protein in Dutch families with familial combined hyperlipidemia. Am. J. Med. Genet. A 130A, 73-75 (2004). (Pubitemid 39121563)
18. Aulchenko, Y. S. et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41, 47-55 (2009).
19. Kathiresan, S. et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41, 56-65 (2009).
20. Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713 (2010).
21. Weissglas-Volkov, D. et al. Investigation of variants identified in caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in Mexican dyslipidemic study samples. Circ. Cardiovasc. Genet. 3, 31-38 (2010).
22. Reynisdottir, S., Eriksson, M., Angelin, B. & Arner, P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J. Clin. Invest. 95, 2161-2169 (1995).
23. Arner, P. et al. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature 478, 110-113 (2011).
24. Pihlajamäki, J. et al. The hormone sensitive lipase gene in familial combined hyperlipidemia and insulin resistance. Eur. J. Clin. Invest. 31, 302-308 (2001). (Pubitemid 32328530)
25. Ylitalo, K. et al. Reduced hormone-sensitive lipase activity is not a major metabolic defect in Finnish FCHL families. Atherosclerosis 153, 373-381 (2000). (Pubitemid 32120336)
26. Pajukanta, P. et al. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families. Arterioscler. Thromb. Vasc. Biol. 17, 841-850 (1997). (Pubitemid 27209260)
27. Zimmermann, R. et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306, 1383-1386 (2004). (Pubitemid 39532517)
28. Nanni, L. et al. Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia. Atherosclerosis 213, 206-211 (2010).
29. Hoffstedt, J., Rydén, M., Wahrenberg, H., van Harmelen, V. & Arner, P. Upstream transcription factor-1 gene polymorphism is associated with increased adipocyte lipolysis. J. Clin. Endocrinol. Metab. 90, 5356-5360 (2005). (Pubitemid 41262301)
30. Marcil, M. et al. Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemia. Arterioscler. Thromb. Vasc. Biol. 26, 1619-1625 (2006). (Pubitemid 44288992)
31. Brouwers, M. C. et al. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J. Lipid Res. 47, 2799-2807 (2006). (Pubitemid 44936093)
32. Venkatesan, S., Cullen, P., Pacy, P., Halliday, D. & Scott, J. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler. Thromb. 13, 1110-1118 (1993). (Pubitemid 23195814)
33. Adiels, M. et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49, 755-765 (2006). (Pubitemid 43357551)
34. Fabbrini, E. et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424-431 (2008). (Pubitemid 351173050)
35. Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343-1351 (2005). (Pubitemid 40629054)
36. Beer, N. L. et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum. Mol. Genet. 18, 4081-4088 (2009).
37. Orho-Melander, M. et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57, 3112-3121 (2008).
38. Ng, M. C. et al. The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 48, 2018-2024 (2005). (Pubitemid 41416912)
39. Zeggini, E. et al. Variation within the gene encoding the upstream stimulatory factor 1 does not influence susceptibility to type 2 diabetes in samples from populations with replicated evidence of linkage to chromosome 1q. Diabetes 55, 2541-2548 (2006). (Pubitemid 44871154)
40. Meex, S. J. et al. Upstream transcription factor 1 (USF1) in risk of type 2 diabetes: association study in 2000 Dutch Caucasians. Mol. Genet. Metab. 94, 352-355 (2008).
41. Casado, M., Vallet, V. S., Kahn, A. & Vaulont, S. Essential role in vivo of upstream stimulatory factors for a normal dietary response of the fatty acid synthase gene in the liver. J. Biol. Chem. 274, 2009-2013 (1999).
42. Iynedjian, P. B. Identification of upstream stimulatory factor as transcriptional activator of the liver promoter of the glucokinase gene. Biochem. J. 333 (Pt 3), 705-712 (1998). (Pubitemid 28398539)
43. Packard, C. J. & Shepherd, J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17, 3542-3556 (1997). (Pubitemid 28028567)
44. Verseyden, C., Meijssen, S. & Castro Cabezas, M. Postprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemia. J. Lipid Res. 43, 274-280 (2002). (Pubitemid 34184014)
45. Babirak, S. P., Brown, B. G. & Brunzell, J. D. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler. Thromb. 12, 1176-1183 (1992).
46. López-Ruiz, A. et al. Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene. Lipids Health Dis. 8, 12 (2009).
47. Campagna, F. et al. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the β3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism 51, 1298-1305 (2002). (Pubitemid 35174152)
48. Yang, W. S. et al. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J. Lipid Res. 37, 2627-2637 (1996).
49. Reymer, P. W. et al. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum. Mol. Genet. 4, 1543-1549 (1995).
50. Yang, W. S., Nevin, D. N., Peng, R., Brunzell, J. D. & Deeb, S. S. A mutation in the promoter of the lipoprotein lipase (LPL) gene in a patient with familial combined hyperlipidemia and low LPL activity. Proc. Natl Acad. Sci. USA 92, 4462-4466 (1995).
51. Nevin, D. N., Brunzell, J. D. & Deeb, S. S. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler. Thromb. 14, 869-873 (1994).
52. Gagne, E., Genest, J. Jr, Zhang, H., Clarke, L. A. & Hayden, M. R. Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. Arterioscler. Thromb. 14, 1250-1257 (1994).
53. Hoffer, M. J. et al. Gender-related association between the-93T->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis 138, 91-99 (1998). (Pubitemid 28255157)
54. de Bruin, T. W. et al. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidaemia. Eur. J. Clin. Invest. 26, 631-639 (1996). (Pubitemid 26273710)
55. Reiber, I. et al. Postprandial triglyceride levels in familial combined hyperlipidemia. The role of apolipoprotein E and lipoprotein lipase polymorphisms. J. Nutr. Biochem. 14, 394-400 (2003). (Pubitemid 36952659)
56. Hoffer, M. J. et al. The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia. Atherosclerosis 151, 443-450 (2000). (Pubitemid 30618761)
57. Gehrisch, S. et al. Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia. J. Mol. Med. (Berl.) 77, 728-734 (1999).
58. Eichenbaum-Voline, S. et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 167-174 (2004). (Pubitemid 38082429)
59. Groenendijk, M., Cantor, R. M., Funke, H. & Dallinga-Thie, G. M. Two newly identified SNPs in the APO AI-CIII intergenic region are strongly associated with familial combined hyperlipidaemia. Eur. J. Clin. Invest. 31, 852-859 (2001). (Pubitemid 34592084)
60. Groenendijk, M., De Bruin, T. W. & Dallinga-Thie, G. M. Two polymorphisms in the apo A-IV gene and familial combined hyperlipidemia. Atherosclerosis 158, 369-376 (2001). (Pubitemid 32913646)
61. Groenendijk, M., Cantor, R. M., De Bruin, T. W. & Dallinga-Thie, G. M. New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia. J. Lipid Res. 42, 188-194 (2001). (Pubitemid 32206829)
62. Aouizerat, B. E. et al. Linkage of a candidate gene locus to familial combined hyperlipidemia: lecithin:cholesterol acyltransferase on 16q. Arterioscler. Thromb. Vasc. Biol. 19, 2730-2736 (1999). (Pubitemid 29536050)
63. Hayden, M. R. et al. DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am. J. Hum. Genet. 40, 421-430 (1987). (Pubitemid 17096944)
64. Ribalta, J. et al. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J. Lipid Res. 38, 1061-1069 (1997). (Pubitemid 27281802)
65. Wojciechowski, A. P. et al. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24. Nature 349, 161-164 (1991). (Pubitemid 21912036)
66. Huertas-Vázquez, A. et al. Contribution of chromosome 1q21-q23 to familial combined hyperlipidemia in Mexican families. Ann. Hum. Genet. 68, 419-427 (2004). (Pubitemid 39405952)
67. Wijsman, E. M. et al. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex. Arterioscler. Thromb. Vasc. Biol. 18, 215-226 (1998). (Pubitemid 28277598)
68. Marcil, M. et al. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. J. Lipid Res. 37, 309-319 (1996).
69. Xu, C. F. et al. Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia. Clin. Genet. 46, 385-397 (1994).
70. Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G. & Clift, S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353, 265-267 (1991). (Pubitemid 21896769)
71. Ebara, T., Ramakrishnan, R., Steiner, G. & Shachter, N. S. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99, 2672-2681 (1997). (Pubitemid 27259814)
72. Cohen, R. D. et al. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J. Clin. Invest. 99, 1906-1916 (1997). (Pubitemid 27175938)
73. Pennacchio, L. A. et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294, 169-173 (2001). (Pubitemid 32952971)
74. Nowak, M. et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol. Cell Biol. 25, 1537-1548 (2005). (Pubitemid 40204928)
75. Laurila, P. P. et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30, 346-352 (2010).
76. Mar, R. et al. Association of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ. Res. 94, 993-999 (2004). (Pubitemid 38490078)
77. Rothblat, G. H. & Phillips, M. C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21, 229-238 (2010).
78. Allayee, H., Castellani, L. W., Cantor, R. M., de Bruin, T. W. & Lusis, A. J. Biochemical and genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. Circ. Res. 92, 1262-1267 (2003). (Pubitemid 36723655)
79. Schunkert, H. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 43, 333-338 (2011).
80. Samani, N. J. et al. Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357, 443-453 (2007). (Pubitemid 47204873)
81. Civeira, F. et al. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. J. Am. Coll. Cardiol. 52, 1546-1553 (2008).
82. Rauh, G. et al. Genetic evidence from 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia. Atherosclerosis 83, 81-87 (1990). (Pubitemid 20210748)
83. Austin, M. A. et al. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia. Genet. Epidemiol. 8, 287-297 (1991).
84. Houlston, R., Lewis, B. & Humphries, S. E. Polymorphisms of the apolipoprotein B and E genes and their possible roles in familial and non-familial combined hyperlipidaemia. Dis. Markers 9, 319-325 (1991).
85. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003). (Pubitemid 36666925)
86. Abifadel, M. et al. A PCSK9 variant and familial combined hyperlipidaemia. J. Med. Genet. 45, 780-786 (2008).
87. Brouwers, M. C. et al. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia. Clin. Sci. (Lond.) 121, 397-403 (2011).
88. Zeng, L. et al. ATF6 modulates SREBP2-mediated lipogenesis. EMBO J. 23, 950-958 (2004). (Pubitemid 38418761)
89. Ericsson, S., Eriksson, M., Berglund, L. & Angelin, B. Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy. J. Intern. Med. 232, 313-320 (1992).
90. Hicks, A. A. et al. Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet. 5, e1000672 (2009).
91. Horswell, S. D., Ringham, H. E. & Shoulders, C. C. New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia. J. Lipid Res. 50 (Suppl.), S370-S375 (2009).
92. Naukkarinen, J. et al. Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. PLoS Genet. 6, e1000976 (2010).
93. Weissglas-Volkov, D. et al. Common hepatic nuclear factor-4α variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes 55, 1970-1977 (2006). (Pubitemid 44509969)
94. Plaisier, C. L. et al. A systems genetics approach implicates USF1, FADS3, and other causal candidate genes for familial combined hyperlipidemia. PLoS Genet. 5, e1000642 (2009).
95. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747-753 (2009).
96. Glazier, A. M., Nadeau, J. H. & Aitman, T. J. Finding genes that underlie complex traits. Science 298, 2345-2349 (2002). (Pubitemid 36014199)
97. Wijsman, E. M. et al. Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families. Hum. Genet. 127, 705-719 (2010).
98. Sanna, S. et al. Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability. PLoS Genet. 7, e1002198 (2011).
99. van der Vleuten, G. M. et al. The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia. Int. J. Obes. (Lond.) 30, 892-898 (2006). (Pubitemid 43801187)
100. van der Kallen, C. J. et al. Genome scan for adiposity in Dutch dyslipidemic families reveals novel quantitative trait loci for leptin, body mass index and soluble tumor necrosis factor receptor superfamily 1A. Int. J. Obes. Relat. Metab. Disord. 24, 1381-1391 (2000).
101. Brouwers, M. C. et al. Longitudinal differences in familial combined hyperlipidemia quantitative trait loci. Arterioscler. Thromb. Vasc. Biol. 26, e118-e119 (2006). (Pubitemid 44305391)
102. Allayee, H. et al. Locus for elevated apolipoprotein B levels on chromosome 1p31 in families with familial combined hyperlipidemia. Circ. Res. 90, 926-931 (2002). (Pubitemid 34633886)
103. Lass, A., Zimmermann, R., Oberer, M. & Zechner, R. Lipolysis-a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog. Lipid Res. 50, 14-27 (2011).
104. Eurlings, P. M., van der Kallen, C. J., Vermeulen, V. M. & de Bruin, T. W. Variants in the PPARgamma gene affect fatty acid and glycerol metabolism in familial combined hyperlipidemia. Mol. Genet. Metab. 80, 296-301 (2003). (Pubitemid 37324715)
105. Pihlajamäki, J. et al. The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 151, 567-574 (2000). (Pubitemid 30618776)
106. Gagnon, F. et al. Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia. Hum. Genet. 117, 494-505 (2005). (Pubitemid 41236371)
107. Lee, J. C. et al. USF1 contributes to high serum lipid levels in Dutch FCHL families and U. S. whites with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 27, 2222-2227 (2007). (Pubitemid 350287253)
108. van der Vleuten, G. M. et al. The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia. J. Lipid Res. 48, 193-200 (2007). (Pubitemid 46052911)
109. Badzioch, M. D. et al. Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan. Arterioscler. Thromb. Vasc. Biol. 24, 1942-1950 (2004). (Pubitemid 39350317)
110. Tsukamoto, K., Maugeais, C., Glick, J. M. & Rader, D. J. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J. Lipid Res. 41, 253-259 (2000). (Pubitemid 30117866)
111. Pei, W. D. et al. Apolipoprotein E polymorphism influences lipid phenotypes in Chinese families with familial combined hyperlipidemia. Circ. J. 70, 1606-1610 (2006).
112. Bredie, S. J., Vogelaar, J. M., Demacker, P. N. & Stalenhoef, A. F. Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 126, 313-324 (1996). (Pubitemid 26336668)
113. Barson, J. R., Morganstern, I. & Leibowitz, S. F. Galanin and consummatory behavior: special relationship with dietary fat, alcohol and circulating lipids. EXS 102, 87-111 (2010).
114. IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet. 7, e1002260 (2011).
115. Perttilä, J. et al. OSBPL10, a novel candidate gene for high triglyceride trait in dyslipidemic Finnish subjects, regulates cellular lipid metabolism. J. Mol. Med. (Berl.) 87, 825-835 (2009).
116. Dallinga-Thie, G. M. et al. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J. Clin. Invest. 99, 953-961 (1997). (Pubitemid 27123632)
117. Allayee, H. et al. Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype. Am. J. Hum. Genet. 63, 577-585 (1998). (Pubitemid 30418640)
118. Deeb, S. S., Nevin, D. N., Iwasaki, L. & Brunzell, J. D. Two novel apolipoprotein A-IV variants in individuals with familial combined hyperlipidemia and diminished levels of lipoprotein lipase activity. Hum. Mutat. 8, 319-325 (1996). (Pubitemid 26412147)
119. Gagnon, F. et al. Evidence of linkage of HDL level variation to APOC3 in two samples with different ascertainment. Hum. Genet. 113, 522-533 (2003). (Pubitemid 37383767)
120. Wong, K. & Ryan, R. O. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr. Opin. Lipidol. 18, 319-324 (2007). (Pubitemid 46743057)
121. Vu-Dac, N. et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J. Biol. Chem. 278, 17982-17985 (2003). (Pubitemid 36799406)
122. Prieur, X. et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J. Biol. Chem. 280, 27533-27543 (2005). (Pubitemid 41076864)
123. van der Vleuten, G. M. et al. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia. Biochim. Biophys. Acta 1772, 81-88 (2007).
124. Liu, Z. K., Hu, M., Baum, L., Thomas, G. N. & Tomlinson, B. Associations of polymorphisms in the apolipoprotein A1/C3/A4/A5 gene cluster with familial combined hyperlipidaemia in Hong Kong Chinese. Atherosclerosis 208, 427-432 (2010).
125. Ribalta, J. et al. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin. Chem. 48, 1597-1600 (2002). (Pubitemid 34925802)
126. Holleboom, A. G., Vergeer, M., Hovingh, G. K., Kastelein, J. J. & Kuivenhoven, J. A. The value of HDL genetics. Curr. Opin. Lipidol. 19, 385-394 (2008).
127. Pihlajamäki, J. et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 20, 1789-1795 (2000). (Pubitemid 30470595)
128. Allayee, H. et al. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J. Lipid Res. 41, 245-252 (2000). (Pubitemid 30117865)
129. Kathiresan, S. et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat. Genet. 41, 334-341 (2009).
130. Aouizerat, B. E. et al. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am. J. Hum. Genet. 65, 397-412 (1999). (Pubitemid 30462997)
131. Matsuoka, Y., Li, X. & Bennett, V. Adducin: structure, function and regulation. Cell. Mol. Life Sci. 57, 884-895 (2000).
132. Beeks, E. et al. Association between the alpha-adducin Gly460Trp polymorphism and systolic blood pressure in familial combined hyperlipidemia. Am. J. Hypertens. 14, 1185-1190 (2001). (Pubitemid 33151472)
133. Weissglas-Volkov, D. et al. Identification of two common variants contributing to serum apolipoprotein B levels in Mexicans. Arterioscler. Thromb. Vasc. Biol. 30, 353-359 (2010).
134. Salazar, J. et al. Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol. Clin. Chem. Lab. Med. 45, 615-620 (2007). (Pubitemid 46709753)
135. Plaisier, C. L. et al. Galanin preproprotein is associated with elevated plasma triglycerides. Arterioscler. Thromb. Vasc. Biol. 29, 147-152 (2009).
136. Kume, T. Specification of arterial, venous, and lymphatic endothelial cells during embryonic development. Histol. Histopathol. 25, 637-646 (2010).
137. Counts, S. E., Perez, S. E., Ginsberg, S. D. & Mufson, E. J. Neuroprotective role for galanin in Alzheimer's disease. EXS 102, 143-162 (2010).
138. Mar-Heyming, R. et al. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 28, 1193-1199 (2008).
139. Soro, A. et al. Genome scans provide evidence for low-HDL-C loci on chromosomes 8q23, 16q24.1-242, and 20q13.11 in Finnish families. Am. J. Hum. Genet. 70, 1333-1340 (2002). (Pubitemid 34450583)
140. Rosenthal, E. A. et al. Linkage and association of phospholipid transfer protein activity to LASS4. J. Lipid Res. 52, 1837-1846 (2011).
141. Huertas-Vazquez, A. et al. A nonsynonymous SNP within PCDH15 is associated with lipid traits in familial combined hyperlipidemia. Hum. Genet. 127, 83-89 (2010).
142. Lilja, H. E. et al. Locus for quantitative HDL-cholesterol on chromosome 10q in Finnish families with dyslipidemia. J. Lipid Res. 45, 1876-1884 (2004).
143. van Himbergen, T. M. et al. Paraoxonase (PON1) is associated with familial combined hyperlipidemia. Atherosclerosis 199, 87-94 (2008).
144. Liu, M. L., James, R. W., Ylitalo, K. & Taskinen, M. R. Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia. Nutr. Metab. Cardiovasc. Dis. 14, 81-87 (2004). (Pubitemid 38813708)
145. Huertas-Vazquez, A. et al. TCF7L2 is associated with high serum triacylglycerol and differentially expressed in adipose tissue in families with familial combined hyperlipidaemia. Diabetologia 51, 62-69 (2008). (Pubitemid 50000014)
146. Parikh, H., Lyssenko, V. & Groop, L. C. Prioritizing genes for follow-up from genome wide association studies using information on gene expression in tissues relevant for type 2 diabetes mellitus. BMC Med. Genomics 2, 72 (2009).
147. Goukassian, D. A. et al. Tumor necrosis factor-α receptor p75 is required in ischemia-induced neovascularization. Circulation 115, 752-762 (2007). (Pubitemid 46294766)
148. Kim, E. Y., Priatel, J. J., Teh, S. J. & Teh, H. S. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J. Immunol. 176, 1026-1035 (2006). (Pubitemid 43099703)
149. Geurts, J. M. et al. Identification of TNFRSF1B as a novel modifier gene in familial combined hyperlipidemia. Hum. Mol. Genet. 9, 2067-2074 (2000).
150. Sáez, M. E. et al. WWOX gene is associated with HDL cholesterol and triglyceride levels. BMC Med. Genet. 11, 148 (2010).